Brooklyn ImmunoTherapeutics, Inc.
(NYSE Amex Equities : NTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
MRKMerck & Co., Inc. -0.06%81.120.7%$1566.02m
JNJJohnson & Johnson 0.19%163.710.7%$997.82m
PFEPfizer Inc. 0.77%43.190.9%$901.42m
ABBVAbbVie, Inc. 0.42%109.221.9%$661.78m
BMYBristol-Myers Squibb Co. -0.38%57.591.0%$625.23m
LLYEli Lilly & Co. 1.07%243.751.1%$585.84m
AZNAstraZeneca Plc 0.93%61.791.0%$310.35m
NVSNovartis AG 0.31%84.930.2%$174.90m
GSKGlaxoSmithKline Plc 0.58%39.780.2%$162.05m
AVIRAtea Pharmaceuticals, Inc. -0.16%12.730.3%$125.28m
RGENRepligen Corp. 1.55%274.956.8%$113.28m
NVONovo Nordisk A/S 1.51%105.990.1%$89.92m
VTRSViatris, Inc. -0.50%13.940.0%$87.91m
SNYSanofi 1.44%49.920.2%$70.53m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.27%139.980.0%$52.50m

Company Profile

Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.